Track market-moving stories before they get noisy

NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a note issued to investors on Monday, Benzinga reports. They presently have a $35.00 target price on the biopharmaceutical company’s stock. Needham & Company LLC’s price target points to a potential upside of 77.87% from the stock’s previous close.

Several other equities analysts also recently issued reports on the company. BMO Capital Markets reduced their price objective on ACADIA Pharmaceuticals from $36.00 to $34.00 and set an “outperform” rating for the company in a research report on Thursday, September 24th. Stifel Nicolaus raised their target price on ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the company a “hold” rating in a research report on Tuesday, July 21st. Morgan Stanley lifted their target price on ACADIA Pharmaceuticals from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 25th. HC Wainwright cut their target price on ACADIA Pharmaceuticals from $37.00 to $33.00 and set a “buy” rating on the stock in a research note on Friday, September 25th. Finally, Citigroup reiterated a “buy” rating and set a $33.00 price target (down from $40.00) on shares of ACADIA Pharmaceuticals in a research report on Friday, September 25th. Thirteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, ACADIA Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $31.34.

Read Our Latest Stock Report on ACAD

ACADIA Pharmaceuticals Trading Up 2.9% ACAD traded up $0.56 on Monday, hitting $19.68. 595,038 shares of the company’s stock were exchanged, compared to its average volume of 1,729,562. The stock has a fifty day moving average of $25.53 and a two-hundred day moving average of $24.04. ACADIA Pharmaceuticals has a twelve month low of $18.39 and a twelve month high of $30.96. The firm has a market cap of $3.39 billion, a PE ratio of 8.86 and a beta of 0.88. ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%. The company had revenue of $308.00 million for the quarter, compared to analysts’ expectations of $296.55 million. During the same period last year, the business posted $0.16 earnings per share. The firm’s quarterly revenue was up 16.4% compared to the same quarter last year. On average, analysts predict that ACADIA Pharmaceuticals will post 0.64 EPS for the current year.

Insider Activity at ACADIA Pharmaceuticals In other news, EVP Mark Schneyer sold 14,292 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $29.22, for a total value of $417,612.24. Following the completion of the transaction, the executive vice president directly owned 67,828 shares in the company, valued at $1,981,934.16. This trade represents a 17.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Elizabeth Thompson sold 16,558 shares of the stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $26.13, for a total transaction of $432,660.54. Following the completion of the transaction, the executive vice president owned 18,994 shares of the company’s stock, valued at $496,313.22. This trade represents a 46.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 36,699 shares of company stock valued at $1,019,894 over the last quarter. Insiders own 26.20% of the company’s stock.

Institutional Inflows and Outflows Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in ACADIA Pharmaceuticals in the 2nd quarter worth approximately $569,634,000. First Trust Advisors LP boosted its stake in ACADIA Pharmaceuticals by 47.3% in the 1st quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company’s stock worth $74,435,000 after purchasing an additional 1,073,834 shares during the period. Dimensional Fund Advisors LP boosted its stake in ACADIA Pharmaceuticals by 8.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,155,160 shares of the biopharmaceutical company’s stock worth $70,222,000 after purchasing an additional 234,186 shares during the period. Palo Alto Investors LP acquired a new position in ACADIA Pharmaceuticals in the 2nd quarter worth approximately $72,461,629. Finally, Pictet Asset Management Holding SA boosted its stake in ACADIA Pharmaceuticals by 31.0% in the 1st quarter. Pictet Asset Management Holding SA now owns 2,026,044 shares of the biopharmaceutical company’s stock worth $44,736,000 after purchasing an additional 478,941 shares during the period. 96.71% of the stock is currently owned by institutional investors.

(Get Free Report)

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders and rare diseases. The company is headquartered in San Diego, California, and serves patients and healthcare providers primarily in the United States.

ACADIA’s commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

See Also Five stocks we like better than ACADIA Pharmaceuticals Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Acadia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 24, 2026, Acadia issued a press release “announc[ing] Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).” Among other data, the Company disclosed that remlifanserin at 60 mg “narrowly missed” the primary endpoint of a clinical tool designed to measure the severity of the disease. 

On this news, Acadia’s stock price fell $3.25 per share, or 12.78%, to close at $22.18 per share on September 24, 2026. 

Then, on September 25, 2026, multiple analysts downgraded Acadia, citing the disappointing trial results. 

On this news, Acadia’s stock price fell $1.50 per share, or 6.76%, to close at $20.68 per share on September 25, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

C4 Therapeutics (NASDAQ:CCCC – Get Free Report) and ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Volatility & Risk C4 Therapeutics has a beta of 3.07, indicating that its share price is 207% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.

Insider & Institutional Ownership 78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations This is a breakdown of recent recommendations and price targets for C4 Therapeutics and ACADIA Pharmaceuticals, as provided by MarketBeat. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 1 0 3 0 2.50 ACADIA Pharmaceuticals 0 4 14 0 2.78 C4 Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 168.99%. ACADIA Pharmaceuticals has a consensus price target of $32.71, indicating a potential upside of 65.37%. Given C4 Therapeutics’ higher probable upside, research analysts clearly believe C4 Therapeutics is more favorable than ACADIA Pharmaceuticals.

Profitability This table compares C4 Therapeutics and ACADIA Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets C4 Therapeutics -289.44% -45.45% -30.90% ACADIA Pharmaceuticals 33.42% 9.03% 6.79% Earnings and Valuation This table compares C4 Therapeutics and ACADIA Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio C4 Therapeutics $35.95 million 10.81 -$104.99 million ($1.00) -3.16 ACADIA Pharmaceuticals $1.14 billion 2.99 $391.00 million $2.22 8.91 ACADIA Pharmaceuticals has higher revenue and earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary ACADIA Pharmaceuticals beats C4 Therapeutics on 11 of the 14 factors compared between the two stocks.

(Get Free Report)

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

About ACADIA Pharmaceuticals (Get Free Report)

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Acadia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 24, 2026, Acadia issued a press release "announc[ing] Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP)."  Among other data, the Company disclosed that remlifanserin at 60 mg "narrowly missed" the primary endpoint of a clinical tool designed to measure the severity of the disease. 

On this news, Acadia's stock price fell $3.25 per share, or 12.78%, to close at $22.18 per share on September 24, 2026. 

Then, on September 25, 2026, multiple analysts downgraded Acadia, citing the disappointing trial results. 

On this news, Acadia's stock price fell $1.50 per share, or 6.76%, to close at $20.68 per share on September 25, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:

Danielle Peyton

Pomerantz LLP

[email protected]

646-581-9980 ext. 7980

SOURCE Pomerantz LLP

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Acadia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 24, 2026, Acadia issued a press release "announc[ing] Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP)."  Among other data, the Company disclosed that remlifanserin at 60 mg "narrowly missed" the primary endpoint of a clinical tool designed to measure the severity of the disease. 

On this news, Acadia's stock price fell $3.25 per share, or 12.78%, to close at $22.18 per share on September 24, 2026. 

Then, on September 25, 2026, multiple analysts downgraded Acadia, citing the disappointing trial results. 

On this news, Acadia's stock price fell $1.50 per share, or 6.76%, to close at $20.68 per share on September 25, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

Key Takeaways Acadia secured a Notice of Allowance that could extend Daybue patent protection to March 2041.ACAD's Daybue sales rose 25% to $226 million in the first half of 2026.Trofinetide's EU approval for Rett syndrome expanded its commercial reach beyond the United States and Canada. Acadia Pharmaceuticals (ACAD - Free Report) has strengthened the intellectual property protection surrounding trofinetide, marketed in the United States as Daybue, following a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO). The allowance covers weight-banded dosing of trofinetide for Rett syndrome and is expected to extend U.S. patent protection from July 2036 to March 28, 2041, subject to issuance of the patent and six months of pediatric exclusivity.

The Notice of Allowance applies to U.S. Patent Application No. 17/590,496, titled “Methods and Compositions for Treatment of Rett Syndrome.” Per Acadia, the USPTO has determined that the application meets the requirements for patentability. The patent is expected to issue after completion of standard administrative steps. The application specifically covers weight-banded dosing of trofinetide, a regimen used for ACAD’s marketed Daybue and Daybue STIX formulations.

The newly allowed patent would add to an existing U.S. method-of-use patent covering trofinetide for the treatment of Rett syndrome, which expires in July 2036. The new protection would therefore extend the period during which Acadia expects to have patent coverage for trofinetide in the United States by almost five years. The allowance is particularly relevant because it covers a dosing regimen incorporated into the marketed products, providing an additional intellectual property layer around the franchise.

Year to date, ACAD shares have lost 23.1% against the industry’s 7.3% growth.

Image Source: Zacks Investment Research

For Acadia, the additional patent protection could help preserve the commercial opportunity for Daybue by potentially delaying generic competition involving the covered weight-banded dosing regimen. Longer patent coverage can also provide greater visibility into the product’s revenue-generating period and support the company’s efforts to maximize the value of trofinetide. However, the allowance does not represent a blanket extension of every patent right associated with trofinetide, making the scope of the specific claims important to the overall exclusivity profile.

ACAD’s Daybue Gains Growth Momentum With Global ExpansionAcadia’s Daybue is the first and only therapy specifically approved by the FDA for Rett syndrome. The FDA approved it in March 2023 for adults and pediatric patients two years of age and older. In December 2025, the FDA approved Daybue STIX, a dye- and preservative-free powder formulation of trofinetide for oral solution, for the same patient population. Unlike the original Daybue oral solution, STIX provides an alternative powder format and greater flexibility regarding dose volume and taste. Acadia made Daybue STIX broadly available in the United States in April 2026.

Acadia reported Daybue net product sales of about $226 million in the first half of 2026, representing growth of approximately 25%. The uptick was primarily driven by continued patient demand and strong uptake of Daybue STIX.

The product also secured an important regulatory milestone in Europe. In August 2026, the European Commission granted marketing authorization for Daybu (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. Acadia said the authorization makes Daybu the first and only treatment approved for Rett syndrome in the EU, expanding trofinetide’s commercial reach beyond the United States and Canada.

ACAD's Zacks Rank & Stocks to ConsiderAcadia currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Precigen (PGEN - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), and AC Immune (ACIU - Free Report) and Aldeyra Therapeutics (ALDX - Free Report) , carrying a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Precigen’s 2026 bottom line have improved from a loss of 2 cents to earnings per share of 24 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 73 cents. PGEN shares have increased 86.9% year to date.

Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.

Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 16.9% year to date.

AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.

Over the past 60 days, loss per share estimates for Aldeyra Therapeutics have narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX shares have plunged 77.6% year to date.

Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.

Key Takeaways ACAD's 60 mg remlifanserin dose narrowly missed the main goal of change from baseline in SAPS-H D at week 6.The 60 mg dose improved CGI-S-ADP by 1.3 points versus 0.9 for placebo, with nominal significance.Acadia will remove the 30 mg arm and focus ongoing phase III studies on the 60 mg dose. Acadia Pharmaceuticals (ACAD - Free Report) announced phase III-enabling top-line results from the phase II portion of the RADIANT study evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). Per ACAD, the findings support continued phase III development of the 60 mg once-daily dose, despite the study narrowly missing the primary efficacy endpoint. The stock was down 12.8% on Thursday, likely reflecting investor disappointment over the efficacy outcome.

Remlifanserin, a novel, highly selective 5HT2A receptor inverse agonist, is being developed as an oral, once-daily treatment for the ADP indication. Acadia’s RADIANT clinical program seamlessly combines phase II and phase III development. In the phase II portion, patients were randomized to receive once-daily remlifanserin at 60 mg or 30 mg, or placebo, and were monitored for six weeks. The study evaluated the efficacy, safety, and tolerability of the remlifanserin doses compared with placebo in ADP patients.

Detailed Results From Phase II Portion of ACAD's ADP ProgramPer Acadia’s phase II ADP data readout, patients receiving 60 mg remlifanserin posted a 12.6-point improvement from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales (SAPS-H+D), compared with a 10.4-point improvement for placebo, at week 6. SAPS-H+D is a clinical measure used to assess the severity of hallucinations and delusions, with greater reductions indicating an improvement in symptoms. The study narrowly missed the primary endpoint of change from baseline in SAPS-H+D.

However, the treatment difference translated into a standardized effect size of 0.26. Acadia noted that the separation between the 60 mg dose and placebo increased through the six-week treatment period, supporting evidence of a dose effect.

Year to date, ACAD shares have lost 16.9% against the industry’s 6.3% growth.

Image Source: Zacks Investment Research

The 60 mg dose also produced a stronger result on the key secondary endpoint, Clinical Global Impression-Severity for ADP (CGI-S-ADP). It is a clinician-rated measure of overall ADP severity, with lower scores indicating less severe symptoms. At week 6, CGI-S-ADP improved by 1.3 points from baseline with 60 mg remlifanserin versus 0.9 points for placebo, demonstrating nominal statistical significance. The treatment difference translated into a standardized effect size of 0.37.

By contrast, the 30 mg dose showed minimal improvement compared with placebo across the efficacy measures. All analyses were conducted in the pre-specified modified full analysis set population.

Safety findings were favorable across both remlifanserin doses. Rates of adverse events, serious adverse events and treatment discontinuations due to adverse events were similar to placebo. The study found no signal of QT prolongation versus placebo, while the dataset did not suggest negative effects on motor symptoms or cognition. No deaths occurred in the remlifanserin treatment groups, adding to the favorable tolerability profile reported in the study.

ACAD's Next StepsAcadia plans to continue enrollment in the two ongoing phase III studies under the RADIANT program evaluating remlifanserin for ADP while amending the program to remove the 30 mg arm and focus development on the 60 mg once-daily dose. The company plans to present detailed phase II safety and efficacy findings at an upcoming medical conference. The additional data could provide greater visibility into the candidate’s efficacy and tolerability profile.

ADP is a serious complication of Alzheimer’s disease involving hallucinations and delusions. Per the Alzheimer’s Association, more than seven million people in the United States are living with Alzheimer’s disease and approximately 30% of patients are estimated to experience psychosis. These symptoms can be frequent, severe and recurrent and are associated with adverse outcomes, including a higher likelihood of nursing home placement and increased morbidity and mortality. Per Acadia, there is currently no FDA-approved drug specifically indicated for ADP, underscoring the unmet medical need.

Acadia is also evaluating remlifanserin in a separate phase II study for the treatment of psychosis associated with Lewy body dementia. The study represents an additional clinical development opportunity for remlifanserin.

ACAD's Zacks Rank & Stocks to ConsiderAcadia currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Precigen (PGEN - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), and AC Immune (ACIU - Free Report) and Aldeyra Therapeutics (ALDX - Free Report) , carrying a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Precigen’s 2026 bottom line have improved from a loss of 2 cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have increased 84.2% year to date.

Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.

Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 15.3% year to date.

AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.

Over the past 60 days, loss per share estimates for Aldeyra Therapeutics have narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX shares have plunged 76.4% year to date.

Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.

Shares of Acadia Pharmaceuticals (NASDAQ:ACAD) fell more than 9% Thursday morning after the company reported mixed Phase 2 results for remlifanserin, its experimental treatment for Alzheimer's disease psychosis. 

The once-daily 60 mg dose eased hallucinations and delusions more than placebo on the trial's main measure, but the result fell just short of statistical significance at six weeks. The 30 mg dose showed little benefit over placebo. 

On a secondary measure of overall symptom severity, the 60 mg dose did significantly outperform placebo. The company said the 60 mg dose kept pulling further ahead of placebo on both measures throughout the six-week study. 

Acadia said it will continue enrolling its two ongoing Phase 3 studies of remlifanserin in Alzheimer's disease psychosis, while amending the program to drop the 30 mg dosage arm and move forward with 60 mg only. 

The drug's safety profile was a bright spot: rates of adverse events, serious adverse events and discontinuations were similar to placebo, with no signal of QT prolongation and no apparent negative impact on motor symptoms or cognition. There were no deaths in either treatment arm. 

Still, analysts at Baird described the update as "incrementally negative," noting that while the 60 mg dose came close to statistical significance with a clean safety profile, investors are likely to be disappointed by the miss.  

The firm flagged the relative drug exposure between the 30 mg and 60 mg doses as a key unresolved question, and said potential enrichment toward more severe patients in the ongoing Phase 3 portion of the study could improve the odds of success. Baird lowered its probability-of-success estimate for remlifanserin in Alzheimer's disease psychosis to 45%. 

There is currently no FDA-approved drug for the treatment of Alzheimer's disease psychosis, a condition that affects roughly 30% of the more than 7 million Americans living with Alzheimer's disease, according to the Alzheimer's Association. 

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) stock is trading lower on Thursday after the company announced topline Phase 2 results from its RADIANT clinical trial program evaluating remlifanserin for Alzheimer’s disease psychosis.

Phase 2 Trial Results For RemlifanserinIn the study, a 60 mg daily dose of remlifanserin led to a -12.6 score change on the primary scale compared to -10.4 for placebo at week six.

Although the treatment narrowly missed statistical significance on the primary measure, it achieved nominal significance on a key secondary endpoint measuring overall disease severity.

Conversely, a lower 30 mg dose provided minimal benefit.

Safety Profile And Phase 3 PlansAcross all dosage arms, remlifanserin demonstrated a favorable safety and tolerability profile. Researchers observed no deaths, no negative impact on cognition or motor functions, and no evidence of heart rhythm abnormalities relative to placebo.

Read Next

Based on these clinical findings, the company will advance its Phase 3 development of daily 60 mg remlifanserin.

Acadia plans to continue enrollment in two ongoing Phase 3 studies while amending the protocol to eliminate the ineffective 30 mg dose.

Additionally, researchers are testing remlifanserin in a separate Phase 2 trial for Lewy body dementia psychosis.

Technical AnalysisACADIA Pharmaceuticals is currently facing bearish momentum, with its price positioned well below key moving averages. The 20-day and 50-day simple moving averages are both above the current price, indicating a negative trend and suggesting traders should be cautious.

The RSI is at 17.49, signaling that ACADIA Pharmaceuticals Inc. is in oversold territory. This low RSI level could indicate a potential for a price rebound, but traders should be wary of the prevailing bearish trend.

MACD is below its signal line, indicating bearish pressure on ACADIA Pharmaceuticals’ stock. This suggests that the downward momentum may continue, and traders should monitor for any signs of a reversal.

Key support is at 21.00, while resistance is at 27.50. If the price approaches support, it may signal a potential reversal, whereas a breach of resistance could indicate a trend change.

The golden cross in July, where the 50-day SMA crossed above the 200-day SMA, initially suggested bullish potential. However, the current price action indicates that traders should remain cautious despite this earlier bullish signal.

Over the past 12 months, ACADIA Pharmaceuticals’ stock has declined by 4.69%, reflecting a longer-term bearish trend.

This performance underscores the need for traders to approach the stock with a careful strategy, given the prevailing downward momentum and technical indicators.

ACAD Price Action: ACADIA Pharmaceuticals shares were down 10.40% at $22.78 at the time of publication on Thursday, according to Benzinga Pro data.

Read Next

Image via Shutterstock

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales (SAPS-H+D), once daily 60 mg remlifanse.

It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD - Free Report) . Shares have added about 0.5% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product SalesAcadia reported second-quarter 2026 earnings of 18 cents per share, which surpassed the Zacks Consensus Estimate of 6 cents. The company had reported earnings of 16 cents per share in the year-ago quarter.

Revenues of $308 million beat the Zacks Consensus Estimate of $294 million, reflecting a 16% year-over-year increase. Growth was supported by higher marketed product sales.

ACAD's Q2 Earnings in DetailAcadia’s revenues comprise net product sales from its two marketed drugs, Daybue and Nuplazid. Reported revenues increased from $264.6 million in the second quarter of 2025 to $308 million in the reported quarter.

The company’s quarterly performance benefited from continued demand for both products. Daybue growth was supported by the uptake of the recently launched Daybue STIX formulation, while Nuplazid benefited from volume growth and increased new-patient prescriptions.

Acadia's Nuplazid Sales Rise Year Over YearReported net product sales of Nuplazid were $183.2 million in the second quarter of 2026, up 9% from $168.5 million in the year-ago period. The drug is approved in the United States for treating hallucinations and delusions associated with Parkinson’s disease psychosis. Nuplazid sales beat the Zacks Consensus Estimate of $181.5 million.

Management stated that Nuplazid’s growth was primarily volume-driven. New-patient prescriptions increased 20% year over year and reached their highest quarterly level since the first quarter of 2018. Acadia also continued to expand engagement with priority health care providers through its enlarged field force.

ACAD's Daybue Sales Jump on STIX UptakeDaybue reported net product sales of $124.8 million, up 30% from $96.1 million in the second quarter of 2025. Daybue is approved in the United States for treating Rett syndrome in adult and pediatric patients two years of age and older. The reported figure beat the Zacks Consensus Estimate of $111.3 million.

Growth was driven largely by volume and strong uptake of Daybue STIX. Approximately 40% of U.S. Daybue patients were receiving STIX by the end of the quarter. The company also recorded a quarterly high in the number of patients returning to Daybue treatment.

Acadia stated that around 60% of total referrals during the quarter came from treatment-naive patients, while 40% represented returning patients. For STIX specifically, 55% of patients switched from the oral solution, while the remaining 45% were new or returning patients.

Acadia’s Operating Expenses Rise in Q2Research and development (R&D) expenses were $82 million in the second quarter of 2026, up 5% from $78 million in the year-ago period.

Selling, general and administrative (SG&A) expenses increased 20% year over year to $160 million from $134 million. The increase reflected investments in expanding the Nuplazid and Daybue field forces and higher marketing spending to support both brands.

Acadia had cash, cash equivalents and investment securities worth $956 million as of June 30, 2026, compared with $851 million as of March 31, 2026.

Acadia Raises Its 2026 Revenue OutlookFollowing the strong quarterly performance, Acadia raised its total revenue guidance for 2026 to a range of $1.24 billion to $1.30 billion. The previous guidance range was $1.22 billion to $1.28 billion.

The company increased its Daybue global net product sales forecast to $480-$510 million from the prior range of $460-$490 million. The revised outlook reflects strong U.S. demand, uptake of STIX and expected contributions from international markets.

Nuplazid net product sales guidance was maintained at $760-$790 million. Management expects the expanded field force to have a greater impact on Nuplazid’s performance later in the year as sales representatives deepen engagement with targeted physicians.

Acadia now expects R&D expense in the range of $355-$380 million, down from the previous range of $385-$410 million. SG&A expenses continue to be expected between $660 million and $700 million.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates review.

The consensus estimate has shifted 59.62% due to these changes.

VGM ScoresAt this time, Acadia has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Acadia has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerAcadia belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Incyte (INCY - Free Report) , has gained 7.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.

Incyte reported revenues of $1.67 billion in the last reported quarter, representing a year-over-year change of +37.7%. EPS of $3.09 for the same period compares with $1.57 a year ago.

For the current quarter, Incyte is expected to post a loss of $3.31 per share, indicating a change of -246.5% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

Incyte has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of A.

Key Takeaways Acadia gained EU approval for Daybu, the first and only approved Rett syndrome treatment in the EU.Daybu is approved for neurobehavioral symptoms of Rett syndrome in adults and children aged five and older.The LAVENDER study showed meaningful improvements in Rett syndrome behavior and global impression. Acadia Pharmaceuticals (ACAD - Free Report) announced that the European Commission (EC) has granted marketing authorization for Daybu (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. The nod marks a major regulatory milestone for the therapy as it is now the first and only treatment approved for this indication in the EU.

The EU approval enables Acadia to expand Daybu’s commercial footprint across all 27 EU member states, as well as Iceland, Liechtenstein and Norway, strengthening the long-term growth potential of its rare disease franchise. As a next step, Acadia will now begin pricing and reimbursement negotiations with relevant national authorities to potentially bring Daybu to patients across the EU.

The EC approval was expected as the advisory committee to the European Medicines Agency adopted a positive opinion in June 2026 recommending the approval of Daybu for Rett Syndrome. It is a rare, neurodevelopmental disorder marked by developmental regression, severe motor impairment and lifelong care needs. The FDA approved trofinetide as the first and only treatment for Rett syndrome in adults and pediatric patients aged two years and older in 2023. The drug is marketed under the brand name Daybue in the United States. Daybue is also marketed (and available) in Canada and Israel for the same indication.

The EC approval is primarily supported by data from the pivotal phase III LAVENDER study, which demonstrated statistically significant and clinically meaningful improvements in key measures of Rett syndrome. The study met its co-primary endpoints, showing benefits on the Rett Syndrome Behavior Questionnaire and the Clinical Global Impression-Improvement scale, indicating that Daybu can improve some of the core neurobehavioral manifestations of the disease that substantially affect patients' daily functioning and caregiver burden.

Year to date, Acadia shares have gained 10.5% compared with the industry’s 11.1% growth.

Image Source: Zacks Investment Research

ACAD's Marketed Drugs Expected to Aid GrowthAcadia’s long-term growth is anchored by its two marketed products, Nuplazid and Daybue. The company continues to target approximately $1.7 billion in combined annual net sales by 2028, including roughly $1 billion for Nuplazid and $700 million for Daybue.

Nuplazid is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. The drug enjoys patent protection in the United States until 2038, giving it a long runway for revenue generation by protecting against generic erosion. In the first half of 2026, Nuplazid generated $350.1 million in net product sales, up 7% from the year-ago period. The increase was primarily driven by higher unit sales, highlighting continued underlying demand for the drug.

Since its launch in 2023, Daybue has witnessed encouraging sales uptake. The therapy generated $226 million in net product sales in the first half of 2026, up 25% year over year, with the increase primarily reflecting higher unit sales. The EU approval of the drug is expected to further boost sales in the upcoming quarters.

Meanwhile, Daybue STIX, a dye- and preservative-free powder formulation of trofinetide, was broadly launched in the United States in the second quarter of 2026. The formulation provides patients and caregivers greater flexibility while maintaining the same efficacy and safety profile as the original oral solution. Its strong uptake contributed to Daybue’s 30% year-over-year sales growth in the second quarter.

Overall, Acadia’s commercial portfolio remains on a solid growth trajectory. Following second-quarter results, the company raised its 2026 Daybue sales projection to $480-$510 million from the previous guided range of $460-$490 million while maintaining Nuplazid sales guidance of $760-$790 million.

ACAD's Zacks Rank & Stocks to ConsiderAcadia currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals (AMRX - Free Report) , Repligen (RGEN - Free Report) and AC Immune (ACIU - Free Report) . AMRX and RGEN currently sport a Zacks Rank #1 (Strong Buy) each, while ACIU carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, earnings estimates for Amneal Pharmaceuticals have increased from $1.00 to $1.02 for 2026. Over the same period, earnings estimates increased from $1.12 to $1.21 for 2027. AMRX shares have risen 42.1% year to date.

Amneal Pharmaceuticals beat earnings in each of the trailing four quarters, delivering an average surprise of 32.82%.

Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.61. RGEN shares have gained 10.6% year to date.

Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.

Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 7.7% year to date.

AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the

Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large MovesACADIA Pharmaceuticals NASDAQ: ACAD outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer’s disease psychosis during a discussion hosted by Canaccord Genuity.

Thomas Garner, Acadia’s chief commercial officer, said the company’s commercial strategy has centered on disease education, targeted outreach to healthcare providers and focused execution in both Parkinson’s disease psychosis and Rett syndrome.

Get ACADIA Pharmaceuticals alerts:

NUPLAZID Growth Strategy Garner said NUPLAZID, Acadia’s treatment for Parkinson’s disease psychosis, has continued to gain traction. New-to-brand prescriptions rose 20% year over year in the most recent quarter, he said.

The company has focused on raising awareness that hallucinations and delusions can occur during the course of Parkinson’s disease, while also educating healthcare providers about treatment options. Garner said Acadia estimates that about 1 million people in the U.S. are living with Parkinson’s disease and that roughly half may experience hallucinations and delusions during their disease course.

Acadia’s “More to Parkinson’s” awareness campaign, involving actor Ryan Reynolds, has contributed to a threefold increase in awareness of Parkinson’s disease psychosis among people living with Parkinson’s disease over the past two to three years, according to Garner.

To expand NUPLAZID’s reach, Acadia increased its sales force by roughly 40% earlier this year. The expansion increased the number of healthcare providers targeted by the company from approximately 5,000 to 6,000 to roughly 10,000 to 10,500, Garner said.

Garner said new treatments entering the broader Parkinson’s disease market could help improve disease awareness and diagnosis, potentially supporting demand for therapies addressing psychosis.

DAYBUE Formulation and Persistence DAYBUE, Acadia’s treatment for Rett syndrome, launched in 2023 and is the first and only approved treatment for the condition, according to Garner. Acadia estimates that about 6,000 people in the U.S., primarily young girls, are living with Rett syndrome.

Long-term patient persistence remains a central commercial focus. Garner said 12-month persistence is above 50% to 55%, while approximately 50% of patients remain on treatment at 18 months. He added that 70% of current DAYBUE patients have been receiving therapy for more than 12 months.

The company recently introduced DAYBUE STIX, a powder formulation that can be mixed with a non-dairy liquid. Garner said the formulation removes certain excipients contained in the earlier oral-solution version and may help Acadia reach treatment-naive patients as well as patients who previously discontinued DAYBUE.

In the second quarter, 60% of DAYBUE business came from the oral solution and 40% came from STIX. In June alone, however, 60% of prescriptions were for STIX, suggesting the newer formulation could become the leading form of the franchise over time, Garner said. He noted that some patients may remain on the oral solution because of the complexity of Rett syndrome and caregiver preferences.

Acadia also sees an opportunity to reengage approximately 1,000 Rett syndrome patients who previously tried and later stopped DAYBUE.

European and Japanese Expansion Garner said Acadia recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for DAYBUE and is preparing for a European Commission decision. The company plans to launch first in Germany after an EC decision and to submit pricing and reimbursement dossiers in additional priority markets.

Acadia estimates there are between 8,000 and 12,000 people living with Rett syndrome in the European Union, compared with about 6,000 in the U.S. Garner said the European opportunity is larger in patient numbers, though pricing and access conditions will vary by country.

The company is also conducting a DAYBUE trial in Japan. Garner said Acadia is evaluating a partnership-based approach to bringing the treatment to Japanese patients.

Pipeline and Business Development Acadia expects Phase II data for remlifanserin in Alzheimer’s disease psychosis in the September-to-October timeframe. Garner described the indication as a large commercial opportunity, estimating that 30% of the 7 million to 7.5 million people currently living with Alzheimer’s disease in the U.S. may develop psychosis.

He said Acadia believes remlifanserin could be differentiated by a profile suited to elderly patients with complex medical needs, though he emphasized that the company must first see how the data develop.

Al Kildani, Acadia’s senior vice president of investor relations and corporate communications, said the company also has a Phase II trial of remlifanserin in Lewy body dementia underway and expects Phase II data for ACP-211 in major depressive disorder in the latter part of next year.

Garner said Acadia has close to $1 billion in cash and is evaluating business-development opportunities ranging from near-term commercial assets to additions that could strengthen its mid-stage pipeline. He said the company is not required to pursue a transaction and intends to be selective about potential deals.

About ACADIA Pharmaceuticals (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company's flagship product, NUPLAZID® (pimavanserin), received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in ACADIA Pharmaceuticals Right Now?Before you consider ACADIA Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.

While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Acadia Pharmaceuticals (ACAD - Free Report) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.

Analysts' growing optimism on the earnings prospects of this drugmaker is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

Consensus earnings estimates for the next quarter and full year have moved considerably higher for Acadia Pharmaceuticals, as there has been strong agreement among the covering analysts in raising estimates.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate RevisionsThe company is expected to earn $0.15 per share for the current quarter, which represents a year-over-year change of -42.3%.

Over the last 30 days, the Zacks Consensus Estimate for Acadia has increased 18.02% because four estimates have moved higher compared to no negative revisions.

Current-Year Estimate RevisionsThe company is expected to earn $0.40 per share for the full year, which represents a change of -52.4% from the prior-year number.

In terms of estimate revisions, the trend for the current year also appears quite encouraging for Acadia. Over the past month, three estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 6.57%.

Favorable Zacks RankOur research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom LineAcadia shares have added 10.8% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.

Key Takeaways Acadia reported Q2 EPS of 18 cents and revenues of $308M, both above consensus estimates. ACAD posted 16% total revenue growth as Daybue sales rose 30% and Nuplazid sales increased 9%.Acadia raised 2026 revenue guidance to $1.24-$1.30B after strong Q2 product sales. Acadia Pharmaceuticals (ACAD - Free Report) reported second-quarter 2026 earnings of 18 cents per share, which surpassed the Zacks Consensus Estimate of 6 cents. The company had reported earnings of 16 cents per share in the year-ago quarter.

Revenues of $308 million beat the Zacks Consensus Estimate of $294 million, reflecting a 16% year-over-year increase. Growth was supported by higher marketed product sales.

ACAD's Q2 Earnings in DetailAcadia’s revenues comprise net product sales from its two marketed drugs, Daybue (trofinetide) and Nuplazid (pimavanserin). Reported revenues increased from $264.6 million in the second quarter of 2025 to $308 million in the reported quarter.

The company’s quarterly performance benefited from continued demand for both products. Daybue growth was supported by the uptake of the recently launched Daybue STIX formulation, while Nuplazid benefited from volume growth and increased new-patient prescriptions.

Acadia's Nuplazid Sales Rise Year Over YearReported net product sales of Nuplazid were $183.2 million in the second quarter of 2026, up 9% from $168.5 million in the year-ago period. The drug is approved in the United States for treating hallucinations and delusions associated with Parkinson’s disease psychosis. Nuplazid sales beat the Zacks Consensus Estimate of $181.5 million.

Management stated that Nuplazid’s growth was primarily volume-driven. New-patient prescriptions increased 20% year over year and reached their highest quarterly level since the first quarter of 2018. Acadia also continued to expand engagement with priority health care providers through its enlarged field force.

ACAD's Daybue Sales Jump on STIX UptakeDaybue reported net product sales of $124.8 million, up 30% from $96.1 million in the second quarter of 2025. Daybue is approved in the United States for treating Rett syndrome in adult and pediatric patients two years of age and older. The reported figure beat the Zacks Consensus Estimate of $111.3 million.

Growth was driven largely by volume and strong uptake of Daybue STIX, a powder formulation for oral solution. Approximately 40% of U.S. Daybue patients were receiving STIX by the end of the quarter. The company also recorded a quarterly high in the number of patients returning to Daybue treatment.

Acadia stated that around 60% of total referrals during the quarter came from treatment-naive patients, while 40% represented returning patients. For STIX specifically, 55% of patients switched from the oral solution, while the remaining 45% were new or returning patients.

Year to date, Acadia shares have gained 1.7% compared with the industry’s 2.6% growth.

Image Source: Zacks Investment Research

Acadia’s Operating Expenses Rise in Q2Research and development (R&D) expenses were $82 million in the second quarter of 2026, up 5% from $78 million in the year-ago period.

Selling, general and administrative (SG&A) expenses increased 20% year over year to $160 million from $134 million. The increase reflected investments in expanding the Nuplazid and Daybue field forces and higher marketing spending to support both brands.

Acadia had cash, cash equivalents and investment securities worth $956 million as of June 30, 2026, compared with $851 million as of March 31, 2026.

Acadia Raises Its 2026 Revenue OutlookFollowing the strong quarterly performance, Acadia raised its total revenue guidance for 2026 to a range of $1.24 billion to $1.30 billion. The previous guidance range was $1.22 billion to $1.28 billion.

The company increased its Daybue global net product sales forecast to $480-$510 million from the prior range of $460-$490 million. The revised outlook reflects strong U.S. demand, uptake of STIX and expected contributions from international markets.

Nuplazid net product sales guidance was maintained at $760-$790 million. Management expects the expanded field force to have a greater impact on Nuplazid’s performance later in the year as sales representatives deepen engagement with targeted physicians.

Acadia now expects R&D expense in the range of $355-$380 million, down from the previous range of $385-$410 million. SG&A expenses continue to be expected between $660 million and $700 million.

ACAD Advances Its Neurology PipelineAcadia completed enrollment in the phase II portion of the RADIANT program evaluating remlifanserin in Alzheimer’s disease psychosis (ADP). The study enrolled 363 patients, and top-line results are expected between September and October 2026.

The company has also started screening and enrollment in two phase III studies of remlifanserin in ADP. The candidate received Fast Track designation from the FDA for treating hallucinations and delusions associated with ADP.

A separate phase II study of remlifanserin is underway in Lewy body dementia psychosis. Acadia is also evaluating ACP-211 in a phase II study for major depressive disorder, while ACP-711 and ACP-271 are progressing through phase I development.

Acadia also received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending authorization of Daybu for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If approved, Daybu would become the first authorized treatment for Rett syndrome in the EU. A final European Commission decision is expected later in the third quarter of 2026.

ACAD's Zacks Rank & Stocks to ConsiderAcadia currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Harmony Biosciences (HRMY - Free Report) , Repligen (RGEN - Free Report)  and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.20 to $3.33, while estimates for 2027 have increased from $3.64 to $3.87 during the same time. HRMY shares have gained 3.5% year to date.

Harmony Biosciences’ earnings missed estimates in three of the trailing four quarters and beat on the remaining occasion, delivering an average negative surprise of 13.97%.

Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 8.6% year to date.

Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.

Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 156.2% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.

Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large MovesACADIA Pharmaceuticals NASDAQ: ACAD reported second-quarter 2026 revenue of $308 million, representing 17% year-over-year growth on an adjusted basis, as sales of its Rett syndrome therapy DAYBUE and Parkinson’s disease psychosis treatment NUPLAZID increased.

Chief Executive Officer Catherine Owen Adams said the quarter reflected strong commercial execution across both brands, while the company also advanced its pipeline, led by remlifanserin for Alzheimer’s disease psychosis.

Get ACADIA Pharmaceuticals alerts:

DAYBUE generated $125 million in second-quarter net sales, up 30% from a year earlier. NUPLAZID produced $183 million in net sales, up 10% year over year on an adjusted basis. ACADIA raised its full-year DAYBUE sales outlook while maintaining its NUPLAZID guidance.

DAYBUE STIX Drives Growth DAYBUE growth was driven primarily by volume, including adoption of DAYBUE STIX, the company’s powder-for-oral-solution formulation. Chief Commercial Officer Thomas Garner said approximately 40% of U.S. DAYBUE patients were receiving STIX by the end of the quarter.

Garner said the expanded launch beyond Centers of Excellence helped engage new patients and bring previously discontinued patients back to therapy. The number of patients returning to DAYBUE reached a record during the quarter, he said.

Of referrals during the quarter across DAYBUE formulations, about 60% came from treatment-naive patients and 40% from returning patients, according to Garner. Looking specifically at STIX users, he said 55% of existing patients were switching from the oral solution, while 45% were new or returning patients. Among that latter group, approximately 60% were new patients and 40% were returning patients.

ACADIA raised its 2026 DAYBUE net sales guidance to $480 million to $510 million, from a prior range of $460 million to $490 million. The outlook includes expected initial European commercial sales in the fourth quarter.

The company recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, for trofinetide, the active ingredient in DAYBUE, following a re-examination process. ACADIA expects a European Commission decision later in the third quarter and plans to launch in Germany in early fourth quarter, followed by other European markets as reimbursement approvals are obtained.

Garner said ACADIA expects less than 50% of its stated $700 million DAYBUE sales target for 2028 to come from Europe. The company said it currently expects roughly 15% of 2028 DAYBUE sales to come from outside the U.S., subject to reimbursement decisions and pricing negotiations.

NUPLAZID Prescription Momentum Continues NUPLAZID’s adjusted 10% sales growth was primarily volume-driven, with volume up 8% year over year. Garner said new patient prescriptions increased 20% from a year earlier and reached their highest quarterly level since the first quarter of 2018.

The company has expanded its commercial field force and said it is beginning to see benefits from that investment, which it had expected to take six to nine months to ramp. Since February, the expanded team has reached more than 12,000 priority healthcare providers, according to Garner.

ACADIA also cited direct-to-consumer awareness efforts, including its “Mind Your Mind” and “More to Parkinson’s” campaigns during Parkinson’s Awareness Month in April. Garner said the campaigns produced record audience reach and increased branded and unbranded patient conversion sequentially.

NUPLAZID refill and restart rates were in line with the company’s expectations, Garner said in response to an analyst question. ACADIA maintained its 2026 NUPLAZID net sales guidance of $760 million to $790 million and expects stronger year-over-year growth in the fourth quarter than in the third quarter as the field-force expansion gains traction.

Remlifanserin Data Expected This Fall ACADIA completed enrollment in the phase II portion of its RADIANT study of remlifanserin in Alzheimer’s disease psychosis. Executive Vice President and Head of Research and Development Elizabeth Thompson said top-line results are now expected between September and October.

The Food and Drug Administration granted Fast Track designation to remlifanserin for Alzheimer’s disease psychosis. ACADIA has also begun screening and enrollment in its phase III studies under an operationally seamless phase II/phase III program design.

Thompson said the phase II portion enrolled 363 patients and is powered at 80% to detect a 0.4 effect size on the Scale for the Assessment of Positive Symptoms Hallucinations and Delusions, or SAPS H&D. The phase III studies are currently enrolling placebo, 30-milligram, and 60-milligram dosing arms, with the company retaining the ability to modify the phase III program after reviewing phase II data.

ACADIA estimates remlifanserin could have $4 billion in peak sales potential across Alzheimer’s disease psychosis and Lewy body dementia psychosis. Management said it currently views that opportunity as roughly 60% attributable to Alzheimer’s disease psychosis and 40% to Lewy body dementia psychosis, though the split will depend on clinical data and the competitive environment.

Elsewhere in the pipeline, ACADIA expects phase III trofinetide data from Japan between September and November and plans a potential regulatory submission in Japan in 2027. The Japanese trial includes roughly 20 patients and is intended primarily to provide experience in Japanese patients, with ACADIA’s prior LAVENDER data expected to serve as the primary basis of a future filing package.

Expenses, Cash and Updated Outlook Research and development expense was $82 million in the quarter, compared with $78 million a year earlier. Selling, general and administrative expense rose to $160 million from $134 million, reflecting investments in the DAYBUE and NUPLAZID field forces and marketing support for both brands.

Chief Financial Officer Mark Schneyer said ACADIA ended the quarter with $956 million in cash. The company now expects 2026 total revenue of $1.24 billion to $1.3 billion.

ACADIA lowered its expected 2026 R&D expense range to $355 million to $380 million, from prior guidance of $385 million to $410 million. Schneyer said the reduction reflected a business-development milestone shifting to 2027 and selected portfolio prioritization decisions. Other fiscal-year guidance ranges were unchanged.

About ACADIA Pharmaceuticals (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company's flagship product, NUPLAZID® (pimavanserin), received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in ACADIA Pharmaceuticals Right Now?Before you consider ACADIA Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.

While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

- Second quarter DAYBUE® GAAP net sales of $125 million, up 30% year-over-year driven by strong uptake of DAYBUE STIX

- Second quarter NUPLAZID® GAAP net sales of $183 million, up 10% year-over-year on a non-GAAP adjusted basis

- Increased full year 2026 total revenue guidance to $1.24 to $1.30 billion, reflecting higher DAYBUE guidance of $480 to $510 million and reaffirmed NUPLAZID guidance of $760 to $790 million

- Topline results from the Phase 2 remlifanserin study in Alzheimer’s disease psychosis anticipated September to October 2026

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2026.

“Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “For DAYBUE, continued patient demand and robust uptake of STIX drove another quarter of strong performance. For NUPLAZID, we continued to see strong momentum, especially in new-to-brand prescriptions as our recently expanded sales force gained traction in the field. We remain confident that both franchises are on track to achieve our long-term ambition of approximately $1.7 billion in annual net sales in 2028. Looking ahead, we are excited about the anticipated topline results from our Phase 2 program evaluating remlifanserin in Alzheimer's disease psychosis in the September to October timeframe, which we believe represents a potentially transformational opportunity for Acadia.”

Company Updates

Completed enrollment in the Phase 2 portion of the RADIANT program evaluating remlifanserin in Alzheimer's disease psychosis and initiated Phase 3 screening and enrollment; topline Phase 2 results are expected in September to October 2026. Received FDA Fast Track designation for remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis, recognizing its potential to address a significant unmet medical need. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If approved by the European Commission, DAYBU would become the first authorized treatment for Rett syndrome in the European Union. Financial Results

Revenues

GAAP total revenues, comprised of net product sales from NUPLAZID and DAYBUE, were $308 million for the second quarter of 2026, up 16% as compared to GAAP total revenues of $265 million in the second quarter of 2025, and up 17% as compared to non-GAAP adjusted total revenues of $262 million in the second quarter of 2025.

GAAP net product sales of NUPLAZID were $183 million for the second quarter of 2026, up 9% compared to GAAP net product sales of $168 million for the second quarter of 2025, and up 10% as compared to non-GAAP adjusted net product sales of $166 million for the second quarter of 2025.

Net product sales of DAYBUE were $125 million for the second quarter of 2026, an increase of 30% as compared to $96 million for the second quarter of 2025.

A reconciliation of NUPLAZID non-GAAP adjusted net product sales and non-GAAP adjusted total revenues is provided in Table 1. A description of these adjustments is included under ‘Non-GAAP Financial Measures.’

Research and Development

Research and development expenses for the second quarter of 2026 were $82 million, compared to $78 million for the same period of 2025.

Selling, General and Administrative

Selling, general and administrative expenses for the second quarter of 2026 were $160 million, compared to $134 million for the same period of 2025.

Net Income

For the second quarter of 2026, Acadia reported net income of $32 million, or $0.18 per diluted share, compared to a net income of $27 million, or $0.16 per diluted share, for the same period in 2025.

Cash and Investments

At June 30, 2026, Acadia’s cash, cash equivalents, and investment securities totaled $956 million, compared to $820 million at December 31, 2025.

Full Year 2026 Financial Guidance (GAAP):

Acadia is updating its 2026 guidance:

Total revenues revised to a range of $1.24 to $1.30 billion, up from the previous range of $1.22 to $1.28 billion. NUPLAZID net product sales in the range of $760 to $790 million. DAYBUE (including all forms of trofinetide) global net product sales in the range of $480 to $510 million, up from the previous range of $460 to $490 million. R&D expense in the range of $355 to $380 million, down from the previous range of $385 to $410 million. SG&A expense in the range of $660 to $700 million. Conference Call and Webcast Information

Acadia will host a conference call to discuss the second quarter 2026 results today, Tuesday, August 4, 2026 at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.

About NUPLAZID® (pimavanserin)

Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID.

About DAYBUE® (trofinetide)

Trofinetide is a synthetic version of a naturally occurring molecule known as the tripeptide glycine-proline-glutamate (GPE). The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown. Trofinetide was approved for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older by the U.S. Food and Drug Administration in March 2023 under the trade name DAYBUE or DAYBUE STIX.

About Acadia Pharmaceuticals

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.

Non-GAAP Financial Measures

This press release contains the following financial measures that do not comply with U.S. generally accepted accounting principles (GAAP): non-GAAP adjusted net product sales for NUPLAZID for the second quarter of 2025 and non-GAAP adjusted total revenues for the second quarter of 2025. In preparing these non-GAAP financial results, the Company includes adjustments made to reflect the impact of a change in estimate related to NUPLAZID IRA rebate accruals. Please refer to our press release dated February 25, 2026, for additional details. These non-GAAP financial measures complement GAAP results and are used by management to analyze financial performance and evaluate period-to-period changes. Management believes these non-GAAP financial measures are useful to investors and other users of the Company’s financial statements to facilitate period-to-period comparability. These non-GAAP financial measures are not meant to be considered as a substitute for comparable GAAP measures; should be read in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are unlikely to be comparable with non-GAAP disclosures released by other companies.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential,” “guidance,” “continue” and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) our business strategy, objectives and opportunities, including support for and innovations in our pipeline assets and business development opportunities, sales growth for DAYBUE and uptake in DAYBUE STIX, and potential for enhanced shareholder value; (ii) the momentum and expectations for NUPLAZID with the expanded sales force, (iii) the FDA’s potential review of a new drug application for remlifanserin as a treatment for Alzheimer’s disease psychosis, (iv) the receipt and timing of the topline results of the RADIANT Phase 2 study, the transformational opportunity of those results, and the enrollment of the Phase 3 portion of the RADIANT development program, (v) potential approval of DAYBU (trofinetide) in the European Union, (vi) plans for, including timing, development and progress of commercialization or regulatory timelines for our products and our product candidates; (vii) benefits to be derived from and efficacy of our products, including the potential advantages of our products; and (viii) our estimates regarding our future financial performance, profitability, capital requirements or expenses, including our full year 2026 financial guidance and anticipated net product sales by the end of 2028. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our dependency on the continued successful commercialization of our products and our ability to maintain or increase sales of our products; the success of our plans to continue commercial growth; the costs of our commercialization plans and development programs, and the financial impact or revenues from any commercialization we undertake; our ability to obtain necessary regulatory approvals for our product candidates and, if and when approved, market acceptance of our products; the risks associated with clinical trials and their outcomes, including risks of unsuccessful enrollment and negative or inconsistent results; our dependence on third-party collaborators, clinical research organizations, manufacturers, suppliers and distributors; the impact of competitive products and therapies; our ability to generate or obtain the necessary capital to fund our operations; our ability to grow, equip and train our specialized sales forces; our ability to manage the growth and complexity of our organization; our ability to maintain, protect and enhance our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2025 as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.

ACADIA PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(Unaudited)

  Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Revenues

Product sales, net

$

307,959

$

264,566

$

576,021

$

508,882

Total revenues

307,959

264,566

576,021

508,882

Operating expenses

Cost of product sales (1)(2)

28,316

20,734

53,107

41,126

Research and development (2)

81,555

77,951

158,423

156,216

Selling, general and administrative (2)

160,252

133,507

331,271

259,877

Total operating expenses

270,123

232,192

542,801

457,219

(Loss) income from operations

37,836

32,374

33,220

51,663

Interest income, net

7,990

7,243

16,045

15,144

Other income

647

594

1,189

1,183

Income before income taxes

46,473

40,211

50,454

67,990

Income tax expense

14,973

13,545

15,317

22,337

Net income

$

31,500

$

26,666

$

35,137

$

45,653

Earnings per share:

Basic

$

0.18

$

0.16

$

0.21

$

0.27

Diluted

$

0.18

$

0.16

$

0.20

$

0.27

Weighted average common shares outstanding:

Basic

171,603

167,827

171,063

167,321

Diluted

172,851

168,681

172,890

168,219

(1) Includes license fees and royalties

(2) Includes the following stock-based compensation expense

Cost of product sales

$

510

$

18

$

838

$

352

Research and development

$

4,746

$

4,477

$

8,888

$

7,910

Selling, general and administrative

$

11,684

$

9,845

$

21,912

$

17,458

ACADIA PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(Unaudited)

  June 30,
2026

December 31,
2025

(unaudited)

Assets

Cash, cash equivalents and investment securities

$

956,474

$

819,686

Accounts receivable, net

150,642

121,457

Interest and other receivables

15,688

26,774

Inventory

32,372

34,670

Prepaid expenses and other current assets

69,369

59,526

Total current assets

1,224,545

1,062,113

Property and equipment, net

17,107

7,511

Operating lease right-of-use assets

69,424

47,354

Intangible assets, net

103,448

108,893

Restricted cash

7,846

7,845

Long-term inventory

76,301

76,704

Deferred tax assets

240,679

249,879

Other assets

3,550

3,896

Total assets

$

1,742,900

$

1,564,195

Liabilities and stockholders’ equity

Accounts payable

$

44,566

$

10,903

Accrued liabilities

316,870

266,211

Total current liabilities

361,436

277,114

Operating lease liabilities

59,547

40,554

Other long-term liabilities

15,308

19,137

Total liabilities

436,291

336,805

Total stockholders’ equity

1,306,609

1,227,390

Total liabilities and stockholders’ equity

$

1,742,900

$

1,564,195

Table 1. ACADIA PHARMACEUTICALS INC.

NON-GAAP RECONCILIATION

(in millions)

(Unaudited)

  2Q25

2Q26

GAAP NUPLAZID Net Sales

$

168.5

$

183.2

Allocation of 2025 Amount

$

(2.4

)

$

—

Non-GAAP Adjusted NUPLAZID Net Sales

$

166.1

$

183.2

DAYBUE products Net Sales

$

96.1

$

124.8

Non-GAAP Adjusted Total Revenues

$

262.2

$

308.0

More News From Acadia Pharmaceuticals Inc.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 1:30 p.m. Eastern Time. Live webcasts will be accessible on the company's website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation. About Acadia Pharmaceuticals Acadia is commit.

3.49K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Posted by Defense World Staff on Jul 22nd, 2026

Bessemer Group Inc. lifted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 21,126.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,498 shares of the biopharmaceutical company’s stock after buying an additional 149,789 shares during the period. Bessemer Group Inc. owned approximately 0.09% of ACADIA Pharmaceuticals worth $3,350,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC boosted its stake in ACADIA Pharmaceuticals by 44.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 954,855 shares of the biopharmaceutical company’s stock valued at $21,312,000 after acquiring an additional 296,042 shares in the last quarter. Illinois Municipal Retirement Fund grew its holdings in shares of ACADIA Pharmaceuticals by 12.7% during the first quarter. Illinois Municipal Retirement Fund now owns 71,183 shares of the biopharmaceutical company’s stock worth $1,585,000 after purchasing an additional 7,996 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in shares of ACADIA Pharmaceuticals by 30.6% during the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 12,923 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 3,026 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of ACADIA Pharmaceuticals by 3.1% during the first quarter. Principal Financial Group Inc. now owns 768,224 shares of the biopharmaceutical company’s stock worth $17,101,000 after purchasing an additional 22,868 shares in the last quarter. Finally, Fifth Third Bancorp lifted its holdings in shares of ACADIA Pharmaceuticals by 5,053.5% in the 1st quarter. Fifth Third Bancorp now owns 31,694 shares of the biopharmaceutical company’s stock valued at $706,000 after purchasing an additional 31,079 shares during the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at ACADIA Pharmaceuticals In related news, insider James Kihara sold 5,401 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total transaction of $114,393.18. Following the completion of the sale, the insider directly owned 24,509 shares of the company’s stock, valued at $519,100.62. This trade represents a 18.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Mark C. Schneyer sold 3,506 shares of ACADIA Pharmaceuticals stock in a transaction on Monday, May 4th. The shares were sold at an average price of $21.79, for a total transaction of $76,395.74. Following the completion of the transaction, the executive vice president owned 66,145 shares in the company, valued at approximately $1,441,299.55. This trade represents a 5.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 10,239 shares of company stock valued at $219,813 in the last 90 days. Company insiders own 26.20% of the company’s stock.

ACADIA Pharmaceuticals Stock Up 1.4% NASDAQ ACAD opened at $25.43 on Wednesday. ACADIA Pharmaceuticals Inc. has a 52-week low of $19.69 and a 52-week high of $28.35. The business’s 50-day moving average price is $23.05 and its 200 day moving average price is $23.27. The firm has a market cap of $4.35 billion, a P/E ratio of 11.56, a P/E/G ratio of 18.07 and a beta of 0.80.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). ACADIA Pharmaceuticals had a net margin of 34.30% and a return on equity of 9.61%. The company had revenue of $268.10 million for the quarter, compared to analysts’ expectations of $280.25 million. During the same period in the prior year, the company earned $0.11 earnings per share. The firm’s revenue was up 9.7% on a year-over-year basis. As a group, analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.37 earnings per share for the current year.

Wall Street Analyst Weigh In A number of brokerages recently issued reports on ACAD. Weiss Ratings cut ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 1st. HC Wainwright lowered ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, June 30th. Royal Bank Of Canada boosted their price objective on ACADIA Pharmaceuticals from $29.00 to $36.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Citigroup increased their price objective on ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, BMO Capital Markets raised their target price on shares of ACADIA Pharmaceuticals from $34.00 to $36.00 and gave the stock an “outperform” rating in a research report on Tuesday. Thirteen analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.17.

Check Out Our Latest Research Report on ACAD

About ACADIA Pharmaceuticals (Free Report)

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.

See Also Five stocks we like better than ACADIA Pharmaceuticals Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINED.A. Davidson & CO. Has $1.84 Million Holdings in Welltower Inc. $WELL

NEXT HEADLINE »Bessemer Group Inc. Purchases 529,678 Shares of Adamas Trust, Inc. $ADAM

Posted by Defense World Staff on Jul 21st, 2026

Allspring Global Investments Holdings LLC lifted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 44.9% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 954,855 shares of the biopharmaceutical company’s stock after buying an additional 296,042 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.56% of ACADIA Pharmaceuticals worth $21,312,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ACAD. Illinois Municipal Retirement Fund grew its stake in ACADIA Pharmaceuticals by 12.7% during the first quarter. Illinois Municipal Retirement Fund now owns 71,183 shares of the biopharmaceutical company’s stock valued at $1,585,000 after acquiring an additional 7,996 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its holdings in shares of ACADIA Pharmaceuticals by 30.6% during the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 12,923 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 3,026 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of ACADIA Pharmaceuticals by 3.1% during the first quarter. Principal Financial Group Inc. now owns 768,224 shares of the biopharmaceutical company’s stock valued at $17,101,000 after purchasing an additional 22,868 shares in the last quarter. Fifth Third Bancorp grew its position in shares of ACADIA Pharmaceuticals by 5,053.5% during the first quarter. Fifth Third Bancorp now owns 31,694 shares of the biopharmaceutical company’s stock valued at $706,000 after purchasing an additional 31,079 shares in the last quarter. Finally, Hsbc Holdings PLC increased its holdings in shares of ACADIA Pharmaceuticals by 67.4% in the first quarter. Hsbc Holdings PLC now owns 44,008 shares of the biopharmaceutical company’s stock worth $977,000 after purchasing an additional 17,722 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

Wall Street Analysts Forecast Growth A number of equities research analysts recently commented on the company. Bank of America boosted their target price on ACADIA Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $37.00 price target on shares of ACADIA Pharmaceuticals in a report on Monday, June 29th. Citigroup boosted their price objective on ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Canaccord Genuity Group raised their price objective on ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Weiss Ratings cut ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 1st. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $32.94.

View Our Latest Research Report on ACAD

ACADIA Pharmaceuticals Stock Performance Shares of NASDAQ ACAD opened at $25.09 on Tuesday. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $19.69 and a fifty-two week high of $28.35. The company has a market cap of $4.30 billion, a price-to-earnings ratio of 11.40, a PEG ratio of 18.44 and a beta of 0.80. The business’s 50 day moving average price is $22.98 and its 200-day moving average price is $23.28.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The company had revenue of $268.10 million during the quarter, compared to the consensus estimate of $280.25 million. ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The company’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.11 earnings per share. Sell-side analysts predict that ACADIA Pharmaceuticals Inc. will post 0.37 earnings per share for the current year.

Insider Activity at ACADIA Pharmaceuticals In other news, insider James Kihara sold 5,401 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total transaction of $114,393.18. Following the transaction, the insider owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. This represents a 18.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Mark C. Schneyer sold 3,506 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $21.79, for a total value of $76,395.74. Following the transaction, the executive vice president owned 66,145 shares in the company, valued at approximately $1,441,299.55. This represents a 5.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 10,239 shares of company stock valued at $219,813 in the last ninety days. Insiders own 26.20% of the company’s stock.

ACADIA Pharmaceuticals Profile (Free Report)

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.

Featured Stories Five stocks we like better than ACADIA Pharmaceuticals The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAllspring Global Investments Holdings LLC Has $21.26 Million Position in ITT Inc. $ITT

NEXT HEADLINE »Allspring Global Investments Holdings LLC Reduces Stock Position in Sempra Energy $SRE

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on August 4, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived for approximately 90 days. The conference ca.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?